Clik here to view.
A More Consistent USPTO Approach to Patent Eligibility
By: Kevin Kabler, Ph.D.; Andrew Whitehead Subject matter eligibility in the United States has recently become a key issue in patent law that has impacted a wide range of technologies in both the life...
View ArticleClik here to view.
A Dynamic Digital Health Sector Means More and Bigger Deals
By: Michael Esquivel The digital health sector is beginning to mature and investors are pouring more money into more deals, reports Rock Health in its survey of digital health investment in the first...
View ArticleClik here to view.
Martin Shkreli Convicted on Three of Eight Counts of Securities Fraud
By: Lauren Border* and Vikram Iyengar, Ph.D. On Friday, August 4, 2017, a federal court jury in Brooklyn, New York, found Martin Shkreli, former CEO of biopharmaceutical company Retrophin, guilty on...
View ArticleClik here to view.
Digital Health Companies May Find a Faster Path to Market Under the FDA's...
By: Pinar Bailey It looks like the FDA is moving forward—and swiftly—with the digital health plan articulated in FDA Commissioner Scott Gottlieb's June blog post, previously outlined in this post....
View ArticleClik here to view.
Five Takeaways From Fenwick’s Sixth Annual Digital Health Investor Summit
By: Michael Esquivel Fenwick’s Sixth Annual Digital Health Investor Summit started on an upbeat note with Rock Health’s Megan Zweig sharing the venture fund’s mid-year funding report. After the...
View ArticleClik here to view.
USPTO and EPO Examiners Discuss Key Considerations for Filing Effective...
By: Kevin Kabler, Ph.D.; Andrew Whitehead At a symposium and webinar presented by Fenwick & West and Mewburn Ellis, we asked U.S. Patent and Trademark Office and European Patent Office examiners to...
View ArticleClik here to view.
Fenwick's Julia Forbess Talks Biotech Investment and Financing Trends
Fenwick corporate lawyer Julia Forbess discussed biotech investment and financing trends with the BIO Buzz Center at the 2017 BIO Investor Forum. “For 2018, we’re still expecting to see investment in...
View ArticleClik here to view.
JPM Conference Takeaways: Biotech and Biopharma Set for Growth in 2018
By: Michael Shuster Coming off a year that saw a record number of new drug approvals, significant scientific breakthroughs and a year-end tax reform package that both significantly lowers corporate...
View ArticleClik here to view.
Investors Make Big Bets on Diagnostics in Q1 2018
By: Michael Esquivel Two trends stood out in our analysis of private digital health investments in the first quarter of 2018: bigger deals and more investment in companies targeting the regulated...
View ArticleClik here to view.
Digital Health Investment Trends Q2 2018: Megadeals Become the Norm, China...
By: Michael Esquivel Private investment in digital health continued apace in the second quarter of 2018, based on our latest look at deal flow. As the sector has matured, growth in investment levels...
View Article
